These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. Nykänen AI; Krebs R; Tikkanen JM; Raisky O; Sihvola R; Wood J; Koskinen PK; Lemström KB Transplantation; 2005 Jan; 79(2):182-9. PubMed ID: 15665766 [TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor inhibition, a novel pathway to prevent chronic allograft injury. Rintala JM; Savikko J; Palin N; Rintala SE; Koskinen PK; von Willebrand E Transplantation; 2014 Oct; 98(8):821-7. PubMed ID: 25073034 [TBL] [Abstract][Full Text] [Related]
24. The effect of FK778 on the progression of chronic allograft nephropathy in a rat model. Lutz J; Huang H; Deng M; Wagner B; Roos M; Schmaderer C; Strobl M; Heemann U Transplantation; 2007 Mar; 83(6):741-6. PubMed ID: 17414707 [TBL] [Abstract][Full Text] [Related]
25. Change from cyclosporine to combination therapy of mycophenolic acid with the new sphingosine-1-phosphate receptor agonist, KRP-203, prevents host nephrotoxicity and transplant vasculopathy in rats. Fujishiro J; Suzuki C; Kudou S; Yasue T; Hakamata Y; Takahashi M; Murakami T; Hashizume K; Kobayashi E J Heart Lung Transplant; 2006 Jul; 25(7):825-33. PubMed ID: 16818126 [TBL] [Abstract][Full Text] [Related]
26. Protective effects of atorvastatin on chronic allograft nephropathy in rats. Zhang W; Liu M; Wu Y; Zhu P; Yin C; Zhang W; Gu M J Surg Res; 2007 Dec; 143(2):428-36. PubMed ID: 17628598 [TBL] [Abstract][Full Text] [Related]
27. Vascular endothelial growth factor in chronic rat allograft nephropathy. Malmström NK; Kallio EA; Rintala JM; Nykänen AI; Räisänen-Sokolowski AK; Paavonen T; Lemström KB; Koskinen PK Transpl Immunol; 2008 May; 19(2):136-44. PubMed ID: 18503889 [TBL] [Abstract][Full Text] [Related]
28. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388 [TBL] [Abstract][Full Text] [Related]
29. Prevention of cardiac allograft arteriosclerosis by protein tyrosine kinase inhibitor selective for platelet-derived growth factor receptor. Sihvola R; Koskinen P; Myllärniemi M; Loubtchenkov M; Häyry P; Buchdunger E; Lemström K Circulation; 1999 May; 99(17):2295-301. PubMed ID: 10226096 [TBL] [Abstract][Full Text] [Related]
30. Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications. Khanna AK; Plummer MS; Hilton G; Pieper GM; Ledbetter S Circulation; 2004 Dec; 110(25):3822-9. PubMed ID: 15583082 [TBL] [Abstract][Full Text] [Related]
32. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Bran B; Bran G; Hörmann K; Riedel F Int J Oncol; 2009 Jan; 34(1):255-61. PubMed ID: 19082496 [TBL] [Abstract][Full Text] [Related]
34. Effect of graft preservation and acute rejection on hypoxia-inducible factor-1 in rat cardiac allografts. Keränen MA; Nykänen AI; Krebs R; Tuuminen R; Sandelin H; Koskinen PK; Lemström KB Transplant Proc; 2006 Dec; 38(10):3372-3. PubMed ID: 17175275 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of tumor necrosis factor-alpha attenuates myocardial remodeling in rat cardiac allografts. Sihvola RK; Koskinen PK; Pulkkinen VP; Tikkanen JM; Lemström KB J Heart Lung Transplant; 2006 May; 25(5):569-78. PubMed ID: 16678037 [TBL] [Abstract][Full Text] [Related]
36. Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. Tikkanen JM; Hollmén M; Nykänen AI; Wood J; Koskinen PK; Lemström KB Am J Respir Crit Care Med; 2006 Nov; 174(10):1145-52. PubMed ID: 16917119 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic effect of Y-27632 on chronic allograft nephropathy in rats. Liu M; Gu M; Wu Y; Zhu P; Zhang W; Yin C; Zhang WJ J Surg Res; 2009 Nov; 157(1):e117-27. PubMed ID: 19589538 [TBL] [Abstract][Full Text] [Related]
38. Evolution of glomerular basement membrane changes in chronic rejection. Yilmaz A; Yilmaz S; Kallio E; Rapola J; Häyry P Transplantation; 1995 Dec; 60(11):1314-22. PubMed ID: 8525527 [TBL] [Abstract][Full Text] [Related]
39. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508 [TBL] [Abstract][Full Text] [Related]
40. Detection of citrate synthase autoantibodies in rats with chronic allograft nephropathy. Zhang LY; Lu YP; Yang L; Luo GH; Song J; Li YP Transplant Proc; 2009 Dec; 41(10):4366-8. PubMed ID: 20005400 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]